News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Clinuvel Announces Positive Results of First Phase II US Study of SCENESSE® in Orphan Disease Erythropoietic Protoporphyria (EPP)



11/3/2011 7:33:15 AM

BAAR, Switzerland & MELBOURNE, Australia--(BUSINESS WIRE)--Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY), a global biopharmaceutical company with unique expertise on the interaction of light and human skin, today announced positive results of its first US Phase II study of the novel photoprotective drug afamelanotide, known as SCENESSE®.

Read at BioSpace.com


comments powered by Disqus
Clinuvel
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES